Evicenter
MarkdownMedical informationP&T meetings
Inaxaplin (VX-147)

APOL1-mediated kidney disease

Launch
Not announced
Last updated
162 sources

Product information and disease descriptionPlace of product in therapyDisease description

Pathophysiology

6 evidence topics · 8 sources

Gain-of-function cation channel activity of the G1 and G2 variants
Interferon-induced APOL1 expression and second hits